Strategic funding Longevity Biotech has attracted a notable non-dilutive grant from the National MS Society (approximately $316k) and is actively leveraging that funding to advance LBT-3627, signaling validated interest from disease-focused funders and potential for continued grant-aligned partnerships.

Therapeutic focus The company concentrates on peptide-based therapeutics using its Hybridtide scaffold designed for long-acting oral administration, presenting a clear value proposition for partners seeking novel modalities in chronic disease management with convenient dosing.

Clinical pipeline Early-stage program LBT-3627 targets multiple chronic diseases and has potential clinical impact, offering multiple entry points for collaboration, out-licensing, or joint development with pharma and specialty biotech players.

Scale and partnerships With a small team (2-10 employees) and revenue in the low to midCap range, there is an opportunity to engage in sponsored R&D, CRO partnerships, and strategic alliances to accelerate development while maintaining lean operations.

Industry positioning Comparable peers show mid-market revenue and smaller teams; Longevity Biotech can differentiate through its unique peptide scaffold platform and potential for long-acting oral formulations, making it attractive for investors and license deals targeting longevity and disease-modifying therapies.